Navitoclax Plus Jakafi Improves Spleen Volume Reductions in

The recent phase 3 TRANSFORM-1 study concluded that navitoclax combined with Jakafi showed significant spleen volume reductions in patients with myelofibrosis.

Related Keywords

Texas , United States , Houston , American , Naveen Pemmaraju , University Of Texas Md Anderson Cancer Center , Department Of Leukemia , American Society Of Hematology , Annual Meeting , Cancer Center , Myelofibrosis , Bmpn ,